Truvada News and Research

RSS
Quest Diagnostics completes sale of ibrutinib commercialization rights to Royalty Pharma

Quest Diagnostics completes sale of ibrutinib commercialization rights to Royalty Pharma

Reformulated version of anti-HIV gel safe for HIV-negative men and women

Reformulated version of anti-HIV gel safe for HIV-negative men and women

Women's low adherence to daily-dose products in HIV prevention trial suggest different approach needed, researchers say

Women's low adherence to daily-dose products in HIV prevention trial suggest different approach needed, researchers say

Study finds antiretroviral-based strategies to prevent HIV infection among women prove ineffective

Study finds antiretroviral-based strategies to prevent HIV infection among women prove ineffective

Gilead Sciences fourth quarter total revenues increase 18% to $2.59 billion

Gilead Sciences fourth quarter total revenues increase 18% to $2.59 billion

Encouraging results from Gilead’s TAF Phase 2 trial on HIV-1 infection

Encouraging results from Gilead’s TAF Phase 2 trial on HIV-1 infection

Study estimates drug concentrations of Truvada and tenofovir to reduce risk of HIV among MSM

Study estimates drug concentrations of Truvada and tenofovir to reduce risk of HIV among MSM

FDA approves Gilead’s Stribild to treat HIV-1 infection

FDA approves Gilead’s Stribild to treat HIV-1 infection

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Gilead Sciences signs deals with 3 Indian pharmaceutical companies to promote low-cost HIV drugs in developing countries

Gilead Sciences signs deals with 3 Indian pharmaceutical companies to promote low-cost HIV drugs in developing countries

Mylan licenses rights to produce and market generic versions of Gilead HIV/AIDS therapies

Mylan licenses rights to produce and market generic versions of Gilead HIV/AIDS therapies

GlobalPost examines debate surrounding PrEP

GlobalPost examines debate surrounding PrEP

Views on AIDS: More funding will be needed for new attack on HIV; The epidemic hits hard in the South

Views on AIDS: More funding will be needed for new attack on HIV; The epidemic hits hard in the South

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

Gilead Sciences second quarter total revenues increase 13% to $2.41 billion

Merck signs two licensing agreements for investigational HIV drug candidates

Merck signs two licensing agreements for investigational HIV drug candidates

Dapivirine Phase III trial now underway in Africa to treat HIV in women

Dapivirine Phase III trial now underway in Africa to treat HIV in women

AIDS medical textbook designed specifically for patients and doctors in resource-poor regions

AIDS medical textbook designed specifically for patients and doctors in resource-poor regions

Views on AIDS:  Despite advances, still no cure, no vaccine, and indifference grows

Views on AIDS: Despite advances, still no cure, no vaccine, and indifference grows

South Africa making progress against HIV/AIDS, but still more effort needed, health minister says

South Africa making progress against HIV/AIDS, but still more effort needed, health minister says

UNMC's ART injectables can successfully treat HIV infection

UNMC's ART injectables can successfully treat HIV infection